Want to see AU:TRJ full AI Analyst Report?
Top Page
Trajan Group Holdings Ltd
(Sydney:TRJ)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.24
▲(30.56% Upside)
Action:Reiterated
Date:09/24/26
The score is weighed down primarily by weak financial performance—continued net losses and a sharp deterioration in 2026 cash generation—despite a balance sheet with only moderate leverage. Technical indicators are supportive of recent upside momentum, but overbought signals temper that strength, and valuation is constrained by a negative P/E and no dividend data.
Positive Factors
Recurring Consumables Model
Recurring consumable and replacement-part sales can support repeat purchasing because they are embedded in routine laboratory testing. That model can make revenue more resilient than one-time equipment sales and provide a durable base for customer retention and ongoing cross-selling across analytical workflows.
Negative Factors
Unproven Profitability
Trajan has not yet established consistent profitability, with net losses continuing through 2025 and 2026. This limits internally generated capital for expansion, makes earnings power harder to assess, and leaves future returns dependent on a sustained improvement in operating performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Consumables Model
Recurring consumable and replacement-part sales can support repeat purchasing because they are embedded in routine laboratory testing. That model can make revenue more resilient than one-time equipment sales and provide a durable base for customer retention and ongoing cross-selling across analytical workflows.
Read all positive factors
Trajan Group Holdings Ltd (TRJ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$41.27M
Dividend YieldN/A
Average Volume (3M)174.67K
Price to Earnings (P/E)―
Beta (1Y)0.47
Revenue Growth-3.05%
EPS Growth86.01%
CountryAU
Employees620
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding152,863,630
10 Day Avg. Volume84,105
30 Day Avg. Volume174,674
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)0.31
Price to Sales (P/S)0.19
P/FCF Ratio-9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.55Price Target Upside205.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.05
Revenue Forecast (FY)AU$168.53M
Trajan Group Holdings Ltd Business Overview & Revenue Model
Company Description
Headquartered in Ringwood, Australia, and established in 2011, Trajan Group Holdings Limited is a global enterprise focused on designing, manufacturing, marketing, and distributing a diverse range of analytical and life science instruments and ass...
How the Company Makes Money
Trajan Group Holdings Ltd makes money primarily by selling laboratory consumables, components, and related products used in analytical testing workflows. Key revenue streams typically include (i) recurring sales of consumables and replacement part...
Trajan Group Holdings Ltd Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
55
Neutral
Cash Flow
32
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 161.38M | 166.46M | 155.02M | 162.15M | 107.57M |
| Gross Profit | 16.86M | 63.47M | 59.75M | 22.93M | 42.63M |
| EBITDA | 12.96M | 12.76M | -20.36M | 14.16M | 5.14M |
| Net Income | -623.00K | -4.46M | -25.33M | 1.89M | 1.70M |
Balance Sheet | |||||
| Total Assets | 183.94M | 195.63M | 188.00M | 229.04M | 206.78M |
| Cash, Cash Equivalents and Short-Term Investments | 12.62M | 11.85M | 11.24M | 11.04M | 13.16M |
| Total Debt | 57.95M | 55.49M | 56.16M | 61.30M | 66.18M |
| Total Liabilities | 85.47M | 90.01M | 85.15M | 99.51M | 90.27M |
| Stockholders Equity | 98.47M | 105.62M | 102.85M | 129.53M | 116.51M |
Cash Flow | |||||
| Free Cash Flow | -3.17M | 6.74M | 6.43M | 998.00K | -1.28M |
| Operating Cash Flow | 242.00K | 10.83M | 9.47M | 9.55M | 2.13M |
| Investing Cash Flow | -3.42M | -4.09M | -3.04M | -8.55M | -116.38M |
| Financing Cash Flow | 3.36M | -5.64M | -6.40M | -3.36M | 74.69M |
Trajan Group Holdings Ltd Technical Analysis
Neutral
0.18
Price Trends
0.22
Positive
0.23
Positive
0.36
Negative
Market Momentum
0.01
Positive
53.93
Neutral
57.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRJ, the sentiment is Neutral. The current price of 0.18 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.22, and below the 200-day MA of 0.36, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 53.93 is Neutral, neither overbought nor oversold. The STOCH value of 57.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:TRJ.
Trajan Group Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$897.50M | 51.53 | 8.16% | ― | 2.59% | -13.36% | |
57 Neutral | AU$48.94M | 218.18 | 0.93% | ― | 18.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$15.72M | -6.09 | -13.81% | 6.27% | 5.93% | 66.32% | |
47 Neutral | AU$19.08M | -1.38 | -35.10% | ― | -9.10% | 31.75% | |
46 Neutral | AU$41.27M | -67.50 | -0.62% | ― | -3.05% | 86.01% | |
46 Neutral | AU$19.02M | -1.97 | -129.15% | ― | -23.71% | -16.02% |
* Healthcare Sector Average
AU:TRJ
Trajan Group Holdings Ltd
0.26
-0.55
-67.70%
AU:CMP
Compumedics Limited
0.24
-0.11
-32.39%
AU:NAN
Nanosonics Limited
3.04
-1.41
-31.69%
AU:PIQ
Proteomics International Laboratories Ltd.
0.12
-0.25
-68.06%
AU:GSS
Genetic Signatures Ltd.
0.09
-0.27
-76.11%
AU:IDT
IDT Australia Limited
0.04
-0.03
-39.68%
Trajan Group Holdings Ltd Corporate Events
Trajan outlines 2026 shareholder update with strict reliance disclaimers
Oct 7, 2026
Trajan Group Holdings Ltd has released a shareholder presentation dated 8 October 2026 that provides high‑level background on the company and its current positioning in the scientific and medical technology markets. The webinar material is f...
Trajan Schedules 2026 Online AGM and Releases Shareholder Materials
Sep 28, 2026
Trajan Group Holdings Limited, a global analytical science and device company specialising in life sciences tools for biological, food and environmental analysis, operates seven manufacturing sites across multiple regions and supports the shift to...
Trajan Sets Fully Virtual 2026 AGM and Opens Director Nominations
Aug 26, 2026
Trajan Group Holdings Ltd, a global analytical science and device company listed on the ASX, develops and manufactures tools used in life sciences and sample analysis as part of its focus on decentralised, personalised healthcare. The company oper...
Trajan files ASX corporate governance statement and Appendix 4G
Aug 26, 2026
Trajan Group Holdings Ltd has lodged its annual corporate governance statement and the accompanying Appendix 4G with the ASX for the financial year ended 30 June 2026. The statement is hosted on the company’s investor website, reflecting its...
Trajan outlines diversified analytical and life science platform
Aug 26, 2026
Trajan Group Holdings Ltd is a global developer and manufacturer of analytical and life science products founded in 2011 to improve human wellbeing. Its technologies and devices are used to analyse biological, food and environmental samples, suppo...
Trajan lifts margins and H2 earnings as cost cuts set up FY27 rebound
Aug 26, 2026
Trajan Group Holdings reported a mixed FY26, with group revenue down 3.1% to $161.4 million and normalised EBITDA falling 14.7% to $13.2 million, but showed a marked recovery in the second half as operational initiatives took hold. The company imp...
Trajan Posts Modest Loss as Revenue Slips and Dividend Remains Off the Table
Aug 26, 2026
Trajan Group Holdings Limited has released its preliminary final report for the year ended 30 June 2026, showing a 3.1% decline in revenue from ordinary activities to $161.4 million compared with the prior year. The group reported a loss after inc...
Trajan sets date for FY26 results and investor webcast
Aug 13, 2026
Trajan Group Holdings Limited will release its full-year results for the financial year ending 30 June 2026 on 27 August 2026, signalling an upcoming update on its performance in the global analytical science and device market. The company will ho...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.